Patent · US Active

Tivozanib response prediction

US7615353B1 · kind B1 · utility

0Cited by

0References

6Claims

0Family size

Assignee

AVEO Pharmaceuticals, Inc. · US

Inventors

Jie Lin · Dedham, US
Murray Robinson · Malibu, US
Bin Feng · Beijing, CN
Wenping Sun · Shanxi, CN

Key dates

Filing date	Jul 6, 2009
Grant date	Nov 10, 2009
Priority date	—
Expiry date	Jul 6, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

A diagnostic method for predicting quantitatively whether a human tumor will be responsive or resistant (non-responsive) to treatment with the VEGF inhibitor, tivozanib (AV-951), is disclosed. The test is based on application of an algorithm to measurements of expression levels of the genes in a predictive gene set.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.